A correction may be in store for Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) shares?

Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) closed the day trading at $17.01 up 6.11% from the previous closing price of $16.03. In other words, the price has increased by $+0.98 from its previous closing price. On the day, 3673644 shares were traded.

Ratios:

For a better understanding of CPRX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.68 and its Current Ratio is at 2.88. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Oppenheimer on December 21, 2023, initiated with a Outperform rating and assigned the stock a target price of $30.

On August 24, 2022, ROTH Capital Downgraded its rating to Neutral which previously was Buy and also upped its target price recommendation from $10 to $15.50.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 15 when Harper Molly sold 14,000 shares for $14.39 per share. The transaction valued at 201,420 led to the insider holds 0 shares of the business.

Tierney David S sold 50,000 shares of CPRX for $666,250 on Dec 12. The Director now owns 333,541 shares after completing the transaction at $13.32 per share. On Dec 11, another insider, GRANDE ALICIA, who serves as the VP, Treasurer and CFO of the company, sold 60,000 shares for $13.76 each. As a result, the insider received 825,780 and left with 50,557 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CPRX now has a Market Capitalization of 2.03B and an Enterprise Value of 1.89B. As of this moment, Catalyst’s Price-to-Earnings (P/E) ratio for their current fiscal year is 27.92, and their Forward P/E ratio for the next fiscal year is 10.53. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.03 while its Price-to-Book (P/B) ratio in mrq is 4.70. Its current Enterprise Value per Revenue stands at 4.75 whereas that against EBITDA is 15.80.

Stock Price History:

Over the past 52 weeks, CPRX has reached a high of $18.22, while it has fallen to a 52-week low of $11.09. The 50-Day Moving Average of the stock is 14.82, while the 200-Day Moving Average is calculated to be 13.54.

Shares Statistics:

Over the past 3-months, CPRX traded about 1.50M shares per day on average, while over the past 10 days, CPRX traded about 1.72M shares per day. A total of 107.12M shares are outstanding, with a floating share count of 99.84M. Insiders hold about 15.29% of the company’s shares, while institutions hold 64.98% stake in the company. Shares short for CPRX as of Feb 15, 2024 were 5.67M with a Short Ratio of 3.78, compared to 5.96M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 4.77% and a Short% of Float of 5.87%.

Earnings Estimates

Current recommendations for the stock of the company come from 2 analysts. On average, analysts expect EPS of $0.2 for the current quarter, with a high estimate of $0.23 and a low estimate of $0.18, while EPS last year was $0.26. The consensus estimate for the next quarter is $0.27, with high estimates of $0.27 and low estimates of $0.27.

Analysts are recommending an EPS of between $1.8 and $0.81 for the fiscal current year, implying an average EPS of $1.34. EPS for the following year is $1.79, with 4 analysts recommending between $2.17 and $1.46.

Revenue Estimates

3 analysts predict $99.11M in revenue for the current quarter. It ranges from a high estimate of $102.3M to a low estimate of $94.29M. As of the current estimate, Catalyst Pharmaceuticals Inc’s year-ago sales were $85.37M, an estimated increase of 16.10% from the year-ago figure.

A total of 5 analysts have provided revenue estimates for CPRX’s current fiscal year. The highest revenue estimate was $503.59M, while the lowest revenue estimate was $447.38M, resulting in an average revenue estimate of $466.13M. In the same quarter a year ago, actual revenue was $398.2M, up 17.10% from the average estimate. Based on 4 analysts’ estimates, the company’s revenue will be $539.97M in the next fiscal year. The high estimate is $590.34M and the low estimate is $521.07M. The average revenue growth estimate for next year is up 15.80% from the average revenue estimate for this year.

Most Popular

[the_ad id="945"]